by Marisa Wexler – Multiple Sclerosis News Today –
A CAR T-cell therapy from Iaso Biotherapeutics was tolerated well and led to marked improvements in disability for three people with progressive forms of multiple sclerosis (MS), according to early data from a Phase 1 clinical trial.
After a single dose of equecabtagene autoleucel, patients saw rapid and sustained benefits, the company announced. These included improved walking and hand function, along with the disappearance of oligoclonal bands, which are markers of inflammation in the spinal fluid associated with MS.
